OnKure Therapeutics (OKUR) Interest Coverage Ratio (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Interest Coverage Ratio came in at 107.69 in Q1 2026, up 11.31% YoY from 96.74 in Q1 2025, and down 9.79% on a QoQ basis from 98.09 in Q4 2025.
OnKure Therapeutics (OKUR) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Interest Coverage Ratio data on file, last reported at 107.69 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 11.31% year-over-year to 107.69 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 96.95 (up 53.38% YoY) and the FY2025 annual result came in at 110.25, down 18317.1% from the prior year.
- Interest Coverage Ratio fell to 107.69 in Q1 2026, from 98.09 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1.09 in Q3 2023 to a low of 204.98 in Q4 2023.
- A 5-year average of 70.72 and a median of 34.34 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio slumped 17905.02% — and 2023, when it jumped 96.05%.
- Tracing OKUR's Interest Coverage Ratio over 5 years: stood at 141.38 in 2022, then sank by 44.99% to 204.98 in 2023, then soared by 55.72% to 90.77 in 2024, then declined by 8.06% to 98.09 in 2025, then retreated by 9.79% to 107.69 in 2026.
- The last three Interest Coverage Ratio figures came in at 107.69 (Q1 2026), 98.09 (Q4 2025), and 21.99 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | OnKure Therapeutics | 196.98 Mn | 20.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.21 |
| Mar 31, 2026 | -107.69 |
| Dec 31, 2025 | -98.09 |
| Sep 30, 2025 | -21.99 |
| Jun 30, 2025 | -19.23 |
| Mar 31, 2025 | -121.43 |
| Dec 31, 2024 | -90.77 |
| Sep 30, 2024 | -129.35 |
| Jun 30, 2024 | -16.85 |
| Mar 31, 2024 | -185.49 |
| Dec 31, 2023 | -204.98 |
| Sep 30, 2023 | -1.09 |
| Jun 30, 2023 | -1.50 |
| Mar 31, 2023 | -1.36 |
| Dec 31, 2022 | -141.38 |
| Sep 30, 2022 | -18.98 |
| Jun 30, 2022 | -7.67 |
| Mar 31, 2022 | -34.34 |
| Dec 31, 2021 | -0.79 |
| Sep 30, 2021 | -1.44 |